Switching from Invega 9 mg to Risperidone
When switching from Invega (paliperidone) 9 mg to risperidone, use a gradual cross-titration approach: start risperidone at 3-4 mg/day while continuing Invega 9 mg, then taper Invega down over 1-2 weeks as you monitor clinical response.
Key Pharmacological Consideration
Since paliperidone is the major active metabolite of risperidone, you're essentially switching from the metabolite back to the parent compound 1. This creates a unique situation where caution should be exercised when these medications are coadministered for extended periods 1. The FDA label explicitly warns about limited safety data for concomitant use 1.
Recommended Switching Strategy
Cross-Titration Approach
The most recent international guidelines (2025) emphasize that antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication 2. This is the preferred method to minimize:
- Rebound psychotic symptoms
- Withdrawal effects
- Receptor supersensitivity reactions
Specific Dosing Algorithm
Week 1:
- Continue Invega 9 mg daily
- Add risperidone 3 mg/day (split into 1.5 mg BID or 3 mg once daily)
- Monitor for excessive dopamine blockade (EPS, sedation, prolactin effects)
Week 2:
- Reduce Invega to 6 mg daily
- Maintain or increase risperidone to 4 mg/day based on tolerability
- Assess clinical stability
Week 3:
- Discontinue Invega
- Adjust risperidone to target dose (typically 4-6 mg/day for equivalent effect)
Dose Equivalency Considerations
Research suggests that when switching from paliperidone to risperidone, higher doses of paliperidone may be required compared with risperidone 3. Conversely, when going from paliperidone to risperidone, you may need slightly lower risperidone doses than the numerical equivalent. The FDA label indicates that Invega 9 mg corresponds roughly to risperidone 4-6 mg based on steady-state exposure 1.
Critical Pitfalls to Avoid
1. Abrupt Discontinuation
Do not abruptly stop Invega 9 mg and immediately start risperidone. This risks:
- Psychotic relapse during the gap period
- Withdrawal dyskinesia
- Cholinergic rebound (though less likely with these agents)
2. CYP2D6 Polymorphism Issues
Be aware that individual patients may respond differently to risperidone versus paliperidone due to CYP2D6 genetic polymorphism 4. A 2023 case report documented acute psychosis when switching from risperidone to paliperidone in a patient who likely had low-functioning CYP2D6 alleles 4. While you're switching in the opposite direction, this highlights that some patients maintain stability on one agent but not the other, despite their metabolic relationship.
3. Prolonged Overlap
The FDA label warns against extended coadministration of paliperidone with risperidone due to limited safety data 1. Keep the overlap period to 1-2 weeks maximum to avoid:
- Excessive dopamine blockade
- Hyperprolactinemia
- Increased EPS risk
- QTc prolongation
Monitoring Parameters
During the switch (weekly):
- Psychotic symptom severity (positive and negative symptoms)
- Extrapyramidal symptoms (use objective rating scale)
- Sedation level
- Orthostatic vital signs
- Weight
After completion (monthly for 3 months):
- Clinical stability assessment
- Metabolic parameters if not recently checked
- Prolactin level if symptomatic
Special Circumstances
If Patient Has Renal Impairment
Paliperidone is renally cleared while risperidone undergoes hepatic metabolism. If your patient has renal impairment (which may have necessitated dose adjustment of Invega), you may be able to use standard risperidone dosing without adjustment 1.
If Switching Due to Side Effects
If the switch is motivated by paliperidone-related side effects (hyperprolactinemia, EPS), you may opt for a faster taper (7-10 days) while monitoring closely for symptom breakthrough.
If Patient is Unstable
If the patient has active psychotic symptoms, the 2025 INTEGRATE guidelines recommend waiting until stability is achieved before switching 2. Consider addressing inadequate response through dose optimization of the current agent first.
Alternative: Direct Switch with Oral Supplementation
In situations where cross-titration is impractical (patient preference, adherence concerns), you can:
- Stop Invega 9 mg
- Start risperidone 4 mg/day immediately
- Monitor daily for first week for symptom breakthrough
- Adjust dose based on response
However, this carries higher risk and should only be used when the gradual approach is not feasible.